FIPI is primarily used in research settings as a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for breaking down endocannabinoids like anandamide. By inhibiting FAAH, FIPI increases the levels of endogenous cannabinoids, which helps scientists study the endocannabinoid system’s role in pain, inflammation, anxiety, and mood regulation. It has shown potential in preclinical studies for developing treatments for chronic pain and neurological disorders without the psychoactive effects associated with cannabis. FIPI is also used to investigate metabolic pathways involving lipid signaling and has contributed to the development of novel therapeutic agents targeting cannabinoid receptors indirectly.